… with bevacizumab showed better overall progression-free survival benefits compared with
… are warranted to move rationally designed AR-targeted therapies forward into the clinic to …

… androgen receptor with high affinity and blocking androgen … (ENZa) can prolong survival
time for patients with mCRPC [7,8… targets interaction profile but with higher affinity and better …

… of this receptor and has led to the development of rational drug … Early ligand-based drug
design was based on modification … The complexity of PROTAC design has increased as more …

… a rapid, but transient increase in serum LH and hence, testosterone levels – termed a '…
These findings provided the rational for drug discovery screens to identify novel anti-androgens …

… to increased androgen receptor protein … therapies targeting continued AR signaling in
tumors despite these agents remain urgent drug development priorities, as does the development …

… binding of cognate natural ligands, allowing rational drug design for the treatment of PCa.
First of … Median metastasis-free survival increased from 16.2 months in the control arm to 40.5 …

… Fortunately, improved breast cancer survival is correlated with AR expression (54), which
occurs in up to 85% of ER-positive breast cancers and 95% of ER-negative breast cancers (55)…

… drug development in bladder cancer. A significant proportion of … therapeutic targets in UC
remains an unmet need. In this … to target AR in combination with cisplatin in UC, to enhance …

… , increased expression in malignant tissues, significantly improving the survival rate of … , it
has been in the spotlight of drug design and development programs over the past years. Many …

… provide significant improvement in survival among men with prostate cancer, drug resistance
… (ADT) is rational and beneficial in PCa. Although early-stage PCa is mostly mediated by …